Cell and Gene Therapy

CEO & Founder - Biotechnology and Regenerative Medicine at RegenerAge International â„¢ (www.regenerage.clinic) VP of International Clinical Development for Bioquark, Inc. (www.bioquark.com) Chief Clinical Officer at ReAnimaâ„¢ Advanced Biosciences (www.reanima.tech) Westhill University School of Medicine. Mexico Advance Fellow by the American Board of AntiAging and Regenerative Medicine (A4M) Visiting scholar at University of North Carolina at Chapel Hill (Dermatology) Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida !

Served in capacities in private and public practices, as hospital staff physician and as emergency health services coordinator for a variety of private and public institutions throughout Mexico and managed a blood bank from 2009- 2012.Served in capacities in private and public practices, as hospital staff physician and as emergency health services coordinator for a variety of private and public institutions throughout Mexico and managed a blood bank from 2009- 2012.

Dmitry Kaminskiy is an innovative entrepreneur and investor who is active in the fields of Longevity, Precision Medicine, and Artificial Intelligence. Mr.Kaminskiy serves as a trustee of the BioGerontology Research Foundation UK, and he is a managing partner at Deep Knowledge Ventures, an investment fund focused on DeepTech and advanced science projects.

Dmitry Kaminskiy is a frequent speaker on the topics of AI and Longevity. During the last year he spoke at conferences organized in London by The Economist Aging Societies and The Business of Longevity, Financial Times Global Pharmaceutical and Biotechnology Conference, at the Precision Medicine World Conference in Silicon Valley

CEO & Founder - Biotechnology and Regenerative Medicine at RegenerAge International â„¢ (www.regenerage.clinic) VP of International Clinical Development for Bioquark, Inc. (www.bioquark.com) Chief Clinical Officer at ReAnimaâ„¢ Advanced Biosciences (www.reanima.tech) Westhill University School of Medicine. Mexico Advance Fellow by the American Board of AntiAging and Regenerative Medicine (A4M) Visiting scholar at University of North Carolina at Chapel Hill (Dermatology) Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida !

Served in capacities in private and public practices, as hospital staff physician and as emergency health services coordinator for a variety of private and public institutions throughout Mexico and managed a blood bank from 2009- 2012.Served in capacities in private and public practices, as hospital staff physician and as emergency health services coordinator for a variety of private and public institutions throughout Mexico and managed a blood bank from 2009- 2012.

Dr Hassan Soliman has completed his PhD at the age of 30 years from Cambridge University and postdoctoral studies from Stanford University School of Medicine. He is the director of a premier Bio-Soft service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.Dr Hassan Soliman has completed his PhD at the age of 30 years from Cambridge University and postdoctoral studies from Stanford University School of Medicine. He is the director of a premier Bio-Soft service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.

Cell Therapy

Dr. Shah is an Associate Professor at Harvard Medical School and the Director of the Center for Stem Cell Therapeutics and Imaging at Brigham and Women’s Hospital (BWH). He is also the Vice Chair of Research for the Department of Neurosurgery at BWH and a Principal Faculty at Harvard Stem Cell Institute in Boston. Since his move to BWH, he has started a joint Center of Excellence in Biomedicine with KACST and is also directing the new Center.

Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology. Recently, Dr. Shah's work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. In an effort to translate the exciting therapies develped in his laboratory into clinics, he has recently founded biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.